The news: 73% of Medicare beneficiaries said they’re unaware of a recently launched government program that lets eligible members access GLP-1 weight loss medications for a $50 monthly copay, according to a June 2026 eHealth report.

Under the 18-month Medicare GLP-1 Bridge program, which began July 1, Medicare beneficiaries enrolled in Part D with a BMI of 35 or higher, or a lower BMI plus at least one weight-related condition, can receive discounted prescriptions for Eli Lilly's Foundayo or Zepbound KwikPen or Novo Nordisk's Wegovy.

Why it matters: Until now, Medicare has been barred from covering drugs prescribed solely for weight loss, though it does cover GLP-1s when used to treat diabetes and certain other conditions. The change could extend coverage to roughly 3.8 million beneficiaries based on Bridge eligibility criteria, per KFF.

The program could make weight loss medications more financially accessible to a large new population.

• Some 39% of Medicare beneficiaries say they would be interested in using GLP-1 weight loss drugs if covered by their plan, per eHealth.
• Another 16% say they currently use or have previously used GLP-1s for weight loss, suggesting numerous people in this cohort have been paying hundreds of dollars out of pocket each month due to lack of coverage.

However, Medicare beneficiaries still need help understanding key aspects of the program. The Bridge program is scheduled to run only through the end of 2027, so participants’ costs will rise again unless new regulations or private insurance coverage changes take effect. Others may assume they qualify because they meet the FDA's BMI threshold of 30 for GLP-1 weight loss drugs.

Implications for healthcare providers and pharmacies: Doctors' offices and pharmacies will bear the brunt of Medicare members' questions about coverage, costs, and eligibility. That could further strain already overburdened care settings and delay answers to important questions—many Medicare beneficiaries already wait more than a month for non-urgent doctor's appointments, per AARP.

Some large pharmacy players have already rolled out online support tools to address knowledge gaps and could benefit if these resources become trusted destinations for new GLP-1 patients.

Providers, meanwhile, should familiarize themselves with guidance from the government and drugmakers to ensure they can answer patient questions and submit the documentation Medicare will require for prior authorization. Providers should also ensure their telehealth capabilities can accommodate increased demand for appointments, prescription requests, and BMI verification, as many patients are likely to opt for virtual care amid in-person appointment bottlenecks.

This content is part of EMARKETER’s subscription Briefings, where we pair daily updates with data and analysis from forecasts and research reports. Our Briefings prepare you to start your day informed, to provide critical insights in an important meeting, and to understand the context of what’s happening in your industry. Not a subscriber? Click here to get a demo of our full platform and coverage.